Moderna (MRNA) PT Lowered to $348 at Piper Sandler, Following Earnings
Tweet
Share
E-mail
Get Alerts MRNA Hot Sheet
Price: $144.96 +8.73%
Rating Summary:
6 Buy, 21 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 21 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff lowered the price target on Moderna (NASDAQ: MRNA) to $348.00 (from $445.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna (MRNA) PT Raised to $77 at JPMorgan
- Moderna (MRNA) PT Raised to $89 at Morgan Stanley
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Earnings, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
